Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (NASDAQ: ANNX) is a clinical-stage biopharmaceutical company advancing therapies targeting C1q to address neuroinflammatory and autoimmune disorders. This page provides investors and researchers with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements about Annexon’s pipeline candidates including ANX005 for Guillain-Barré syndrome, ANX007 for geographic atrophy, and ANX1502 for systemic autoimmune conditions. Our curated news collection delivers verified press releases and analysis to support informed decision-making.
Key updates include clinical trial progress, scientific presentations, partnership announcements, and regulatory filings. All content is vetted for accuracy and relevance to complement inhibition therapies.
Bookmark this page for streamlined access to Annexon’s latest developments in targeting upstream complement pathways. Check regularly for authoritative updates on novel treatments for diseases with high unmet medical needs.
Annexon, Inc. reported its first quarter 2024 financial results, highlighting multiple value-creating catalysts in their portfolio. Key anticipated milestones include Phase 3 data for ANX005 in Guillain-Barré Syndrome, Phase 3 trial initiation for ANX007 in Geographic Atrophy, and proof-of-concept data for ANX1502 in Chronic Autoimmune Conditions. The company boasts a strong balance sheet with cash of $264.9 million as of March 31, 2024.
Annexon, a biopharmaceutical company, will present at the Bank of America Health Care Conference. President and CEO, Douglas Love, will discuss the company's late-stage clinical platform for neuroinflammatory diseases. The event will be live-streamed on May 14, 2024, at 8:40 a.m. PT.
Annexon presented new data at the ARVO 2024 Annual Meeting showcasing ANX007's significant protection against vision loss in patients with geographic atrophy. The drug demonstrated preservation of key retinal structures, reduction of photoreceptor and RPE loss, and promising preclinical results supporting its mechanism of action. Plans for Phase 3 trials in 2024 were announced, highlighting the drug's potential to deliver functional benefits to patients.
Annexon, Inc. (Nasdaq: ANNX) will present data at the ARVO 2024 Annual Meeting showcasing the neuroprotective effects of ANX007 and C1q inhibition in Geographic Atrophy. The Phase 2 ARCHER trial results will be discussed, highlighting the protection of visual acuity and anatomical structure with ANX007 treatment. New preclinical data on the role of C1q in photoreceptor synapse elimination and the protective effects of C1q blockade in GA will also be presented.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
